Search
Peldesine
go.drugbank.com/drugs/DB02568InvestigationalPeldesine is a potent inhibitor of human CCRF-CEM T-cell proliferation. It has undergone phase I trials for the treatment of Human Immunodeficiency Virus (HIV) infections.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesEstrone sulfate
go.drugbank.com/drugs/DB04574ApprovedEstrone sulfate (as estropipate) is a form of estrogen. It has several uses such as: alleviate symptoms of menopause as hormone replacement therapy, treatment some types of infertility, treatment of some conditions leading to underdevelo...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsLicofelone
go.drugbank.com/drugs/DB04725ExperimentalDeveloped by the German pharmaceutical company, Merckle GmbH, together with EuroAlliance partners Alfa Wassermann and Lacer, licofelone (ML3000) is a dual COX/LOX inhibitor and the first member of this new class of analgesic and anti-inf...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsIproniazid
go.drugbank.com/drugs/DB04818ApprovedWithdrawnWithdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP2D6 InhibitorsTienilic acid
go.drugbank.com/drugs/DB04831ApprovedWithdrawnTienilic acid, or ticrynafen, is a diuretic drug with uric acid-lowering action which was marketed for the treatment of hypertension. It was withdrawn in 1982 after case reports in the United States suggested a link between ticrynafen an...
Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsMaraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalMaraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. I...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesIxabepilone
go.drugbank.com/drugs/DB04845ApprovedInvestigationalIxabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is ...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsCeliprolol
go.drugbank.com/drugs/DB04846ApprovedInvestigationalWithdrawnCeliprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris. It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. In ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesBiricodar
go.drugbank.com/drugs/DB04851InvestigationalThe pipecolinate derivative biricodar (VX-710) is a clinically applicable modulator of P-glycoprotein (Pgp) and multidrug resistance protein (MRP-1).
Categories: P-glycoprotein inhibitorsTirapazamine
go.drugbank.com/drugs/DB04858InvestigationalTirapazamine, also known as SR-4233, is an experimental anticancer drug that is activated in hypoxic conditions. This activation is very useful as this hypoxic state is found in human solid tumors in a common phenomenon known as tumor hy...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 Substrates